Skip to the answer

Cabozantinib (thyroid cancer) Uses, Dosage, Side Effects and Interactions

Brand names
Cometriq

Cometriq was the first cabozantinib (thyroid cancer) product the FDA approved, in November 2012.

Cabometyx

Cabometyx came 3 years after Cometriq (April 2016) as a tablet, a form not listed for Cometriq.

Cabozantinib (sold as Cabometyx tablets) is a kinase inhibitor, a targeted cancer medicine used for advanced kidney cancer, liver cancer, differentiated thyroid cancer and certain neuroendocrine tumors.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Cabozantinib (thyroid cancer)Type a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Cabozantinib (thyroid cancer) in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Cabozantinib (Cabometyx), on the U.S. market since about 2012, is a targeted cancer medicine that blocks MET, VEGFR and RET, proteins tumors use to grow, spread and build blood vessels. For differentiated thyroid cancer it is a later option, used when radioactive iodine is not an option and an earlier VEGFR-targeted drug has stopped working, and it also treats kidney cancer, liver cancer and neuroendocrine tumors. Side effects are common, mainly diarrhea, tiredness, poor appetite and sore, red palms and soles, and doses are often lowered to keep it manageable. Watch above all for bleeding, and call right away for coughing up blood, vomiting blood or black stools.

Key Takeaways From the HelloPharmacist Team

  • Take it once a day on an empty stomach, at least 1 hour before or 2 hours after food, swallowed whole.
  • Expect regular blood pressure checks and urine protein, thyroid and calcium tests, since it can raise blood pressure and strain the heart.
  • Start treating diarrhea at the first loose stool and report it if severe or persistent, since a dose pause or reduction often helps.
  • Avoid grapefruit and St. John’s wort, and have your pharmacist check every new medicine, since many change cabozantinib levels.

How we write and review this content: our editorial policy

Cabozantinib (thyroid cancer) by the Numbers

Earliest FDA record
2012
Rank by Medicaid prescriptions
#1,121 of 1,682 drugs
More prescriptions than 33% of the 1,682 drugs we measure
3,853 prescriptions, Q1–Q4 2025

Patient Information Guide for Cabozantinib (thyroid cancer)

What It’s Used For

Cabometyx tablets are approved for several cancers:

  • Advanced renal cell carcinoma (kidney cancer), and as first treatment together with nivolumab
  • Hepatocellular carcinoma (liver cancer) previously treated with sorafenib
  • Differentiated thyroid cancer in adults and children 12 and older, locally advanced or metastatic, that progressed after VEGFR-targeted therapy and is radioactive iodine-refractory or ineligible
  • Previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors in adults and children 12 and older

How It Works

Cabozantinib blocks the activity of several tyrosine kinases, which are proteins that send growth signals. These include MET, VEGFR-1, -2 and -3, AXL and RET, among others. These proteins are involved in tumor growth, spread, blood vessel formation and drug resistance. Blocking them helps slow the cancer.

Drug Class

Drug Class

  • Kinase Inhibitor
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Kinase Inhibitor

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Protein Kinase Inhibitors

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Cabozantinib (thyroid cancer) in the FDA’s index.

From our Patient Information GuideCabozantinib blocks the activity of several tyrosine kinases, which are proteins that send growth signals. These include MET, VEGFR-1, -2 and -3, AXL and RET, among others. Read How Cabozantinib (thyroid cancer) Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Cabozantinib (thyroid cancer) in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Other protein kinase inhibitors

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Cabometyx is a tablet taken by mouth once daily. Your prescriber sets the dose based on your condition, weight, liver function and other medicines.

  • Take it on an empty stomach, at least 1 hour before or 2 hours after eating.
  • Swallow tablets whole. Do not crush, chew or split them.
  • Do not take a missed dose within 12 hours of the next one.
  • Do not swap tablets for cabozantinib capsules.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Advanced kidney cancer

Adults Usual dose 60 mg once a day
  • 60 mg orally once daily until disease progression or unacceptable toxicity
Adults taking it with nivolumab Usual dose 40 mg once a day

Step by step

  1. 40 mg orally once daily in combination with 240 mg nivolumab every 2 weeks (30-minute intravenous infusion)
  2. -OR- 480 mg nivolumab every 4 weeks (30-minute intravenous infusion)
  3. -OR- 600 mg nivolumab and 10,000 units hyaluronidase subcutaneously over approximately 3-5 minutes every 2 weeks
  4. -OR- 1,200 mg nivolumab and 20,000 units hyaluronidase subcutaneously over approximately 3-5 minutes every 4 weeks
  5. Cabometyx until disease progression or unacceptable toxicity
  6. Nivolumab (or nivolumab and hyaluronidase) until disease progression or unacceptable toxicity for up to 2 years

Liver cancer

For adults previously treated with sorafenib
Usual dose 60 mg once a day
  • 60 mg orally once daily until disease progression or unacceptable toxicity

Thyroid cancer or neuroendocrine tumors

Adults and children 12 years and older weighing 40 kg or more Usual dose 60 mg once a day
  • 60 mg orally once daily until disease progression or unacceptable toxicity
Children 12 years and older weighing less than 40 kg Usual dose 40 mg once a day
  • 40 mg orally once daily until disease progression or unacceptable toxicity

Good to Know for Every Dose

Take on an empty stomach, at least 1 hour before or at least 2 hours after eating

See the Full Dosing Instructions on DailyMed →

Side Effects

Common side effects include:

Common side effects

  • Diarrhea
  • Tiredness (fatigue)
  • Hand-foot skin reaction (redness, pain on palms and soles)
  • Decreased appetite
  • High blood pressure
  • Nausea and vomiting
  • Weight loss
  • Constipation

When to get medical help

  • Call your doctor right away for any bleeding, such as coughing up blood, vomiting blood or black stools. Cabometyx can cause severe and fatal bleeding.
  • Seek help for severe belly pain, fever or signs of infection. Tears in the gut (perforation) and abnormal connections (fistulas) can occur.
  • Get emergency help for chest pain, sudden shortness of breath, leg swelling or stroke symptoms. Blood clots and heart attacks can occur.
  • Tell your doctor if your blood pressure is very high or you have a severe headache. Hypertensive crisis is possible.
  • Report seizures, severe headache, vision changes or confusion. These can signal reversible posterior leukoencephalopathy syndrome (RPLS), a brain swelling condition.
  • Report jaw pain, toothache, gum sores or slow healing after dental work. Osteonecrosis of the jaw can occur.
  • Tell your doctor about severe or persistent diarrhea, or signs of heart failure.
  • Report symptoms of low calcium or underactive thyroid, such as tiredness.

Warnings and Precautions

  • Severe and fatal bleeding can occur. It should not be used with a recent history of bleeding.
  • Gut perforations and fistulas can occur.
  • Blood clots, including heart attack, can occur.
  • High blood pressure and hypertensive crisis can occur.
  • Heart failure can occur.
  • Severe diarrhea, hand-foot skin reaction and protein in the urine can occur.
  • Jaw bone damage and poor wound healing can occur, so stop it at least 3 weeks before surgery.
  • Thyroid problems and low calcium can occur.
  • It can cause fetal harm.

Interactions

Some medicines and foods change cabozantinib levels.

  • Strong CYP3A4 inhibitors raise levels and the risk of side effects.
  • Strong or moderate CYP3A4 inducers lower levels and may reduce effectiveness.
  • Grapefruit and grapefruit juice may raise levels.
  • St. John’s wort may lower levels.

Interactions Listed in the FDA-Approved Label

From the Cabozantinib (thyroid cancer) prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inhibitors
    What happensCoadministration of a cabozantinib capsule formulation with a strong CYP3A4 inhibitor increased cabozantinib exposure, which may increase the risk of exposure-related adverse reactions.
    What to doAvoid coadministration; reduce the CABOMETYX daily dose by 20 mg if it cannot be avoided, and resume the prior dose 2 to 3 days after the inhibitor is stopped.
  • Grapefruit or grapefruit juice
    What happensMay also increase exposure of cabozantinib.
    What to doAvoid grapefruit or grapefruit juice.
  • Strong or moderate CYP3A4 inducers
    What happensCoadministration of a cabozantinib capsule formulation with a strong CYP3A4 inducer decreased cabozantinib exposure, which may reduce efficacy.
    What to doAvoid coadministration; if it cannot be avoided, increase the daily CABOMETYX dose by 20 mg as tolerated, do not exceed 80 mg daily, and resume the prior dose 2 to 3 days after the inducer is stopped.
  • St. John's wort
    What happensMay also decrease exposure of cabozantinib.
    What to doAvoid St. John's wort.
Read the label’s full interactions text

7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Reduce the CABOMETYX dosage if coadministration cannot be avoided. Strong or moderate CYP3A4 inducers: Increase the CABOMETYX dosage if coadministration cannot be avoided. 7.1 Effects of Other Drugs on CABOMETYX Strong CYP3A4 Inhibitors Coadministration of a cabozantinib capsule formulation with a strong CYP3A4 inhibitor increased the exposure of cabozantinib, which may increase the risk of exposure-related adverse reactions. Avoid coadministration of CABOMETYX with strong CYP3A4 inhibitors. Reduce the dosage of CABOMETYX if coadministration with strong CYP3A4 inhibitors cannot be avoided. Avoid grapefruit or grapefruit juice which may also increase exposure of cabozantinib. Strong or Moderate CYP3A Inducers Coadministration of a cabozantinib capsule formulation with a strong CYP3A4 inducer decreased the exposure of cabozantinib, which may reduce efficacy. Avoid coadministration of CABOMETYX with strong or moderate CYP3A4 inducers. Increase the dosage of CABOMETYX if coadministration with strong or moderate CYP3A4 inducers cannot be avoided. Avoid St. John’s wort which may also decrease exposure of cabozantinib.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Recent bleeding history
  • Uncontrolled high blood pressure
  • Moderate liver impairment (dose reduced); severe impairment (avoid)
  • Planned surgery or dental procedures
  • Pregnancy: can harm the baby; use effective birth control during treatment and for 4 months after
  • Breastfeeding: not advised during treatment and for 4 months after
  • Children 12 and older: growth monitoring is needed if growth plates are open
  • Mild or moderate kidney impairment: no dose change needed; no experience in severe kidney impairment
  • Older adults: no overall differences in safety or effectiveness

Overdose

One reported overdose involved a patient who took twice the intended dose for 9 days. The patient had serious memory problems, mental status changes and cognitive disturbance, plus weight loss. Contact your doctor or poison control right away if you take too much.

Half-Life and How Your Body Processes It

Peak levels occur about 3 to 4 hours after a dose. Levels build up with daily dosing, reaching steady state by about day 15. A high-fat meal raised levels in a capsule study, which is why the tablet is taken on an empty stomach. The half-life is about 99 hours. It is mostly broken down by the CYP3A4 enzyme and cleared mainly in feces, with some in urine.

Storage

Store CABOMETYX at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Cabozantinib (thyroid cancer): Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Cabozantinib (thyroid cancer) — the kind of thing our pharmacy team would talk through with you at the counter.

What is Cabometyx used for?

It treats advanced kidney cancer, liver cancer after sorafenib, certain neuroendocrine tumors and differentiated thyroid cancer. For thyroid cancer, it is for people 12 and older whose cancer progressed after VEGFR-targeted therapy and is no longer responding to radioactive iodine, or who cannot have it.

How do I take Cabometyx?

Take it once daily on an empty stomach, at least 1 hour before or 2 hours after eating. Swallow it whole without crushing, chewing or splitting. Follow the dose your prescriber gave you.

What happens if I miss a dose of Cabometyx?

Skip it if your next dose is within 12 hours. Don’t double up. Ask me or your prescriber if you’re unsure.

What side effects should I expect?

Diarrhea, tiredness, sore red palms and soles, low appetite, high blood pressure, nausea and weight loss are common. Call your doctor about bleeding, severe belly pain, chest pain, severe headache, vision changes or jaw pain. Your doctor may lower your dose if side effects are hard to manage.

Can I have grapefruit or take St. John’s wort with Cabometyx?

No, avoid both. Grapefruit may raise cabozantinib levels, and St. John’s wort may lower them. Check with me before starting any new medicine or supplement.

Is Cabometyx safe in pregnancy?

No. It can harm an unborn baby. Use effective birth control during treatment and for 4 months after your last dose, and don’t breastfeed during that time.

Is cabozantinib (thyroid cancer) available over the counter?

No. Cabozantinib (thyroid cancer) is a prescription medicine: every cabozantinib (thyroid cancer) product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was cabozantinib (thyroid cancer) first available?

The earliest FDA record we hold for cabozantinib (thyroid cancer) is from 2012: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when cabozantinib (thyroid cancer) was first used.

What is the brand name of cabozantinib (thyroid cancer)?

Cabozantinib (thyroid cancer) is the generic name. Its brand names are Cometriq and Cabometyx.

What is the generic name of Cometriq?

The generic name of Cometriq is cabozantinib (thyroid cancer). A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is cabozantinib (thyroid cancer)?

Cabozantinib (thyroid cancer) belongs to the drug class Kinase Inhibitor, its established pharmacologic class on the FDA label.

Is there a cabozantinib (thyroid cancer) shortage?

No. Cabozantinib (thyroid cancer) is not on the FDA's drug shortage list as of Nov 21, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the cabozantinib (thyroid cancer) prescribing information (package insert)?

The full FDA-approved prescribing information for cabozantinib (thyroid cancer), also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Exelixis, Inc.'s, revised Oct 19, 2025, and links to it on DailyMed.

Can you crush cabozantinib (thyroid cancer)?

Some forms of cabozantinib (thyroid cancer) are on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: Cabometyx (tablet); Cabozantinib malate (capsule; tablet); Cometriq (capsule). Crushing or splitting a hazardous drug can expose whoever handles it. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Cabozantinib (thyroid cancer)

Skip the scrolling. Ask in your own words and get an answer from Cabozantinib (thyroid cancer)’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Cabozantinib (thyroid cancer)’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Cabozantinib (thyroid cancer) on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Cabozantinib (thyroid cancer) Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Cabozantinib (thyroid cancer) on the U.S. Market: Products, Makers and Brands

How Cabozantinib (thyroid cancer) appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

The FDA lists Cabozantinib (thyroid cancer) products; the earliest marketing or approval year on record is 2012.

2
Brand names ⓘ
2012
Earliest FDA record ⓘ

How Widely Cabozantinib (thyroid cancer) Is Used (Medicaid Data)

How many Cabozantinib (thyroid cancer) prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

3,853
Medicaid prescriptions filled (Q1–Q4 2025)
$93.8M paid by Medicaid, before rebates

How commonly is Cabozantinib (thyroid cancer) prescribed? Of the 1,682 medications we measure, Cabozantinib (thyroid cancer) ranks #1,121 by Medicaid prescriptions — more than 33% of them.

Where Cabozantinib (thyroid cancer) ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Cabozantinib (thyroid cancer) product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 40 mg oral tablet is the most-dispensed Cabozantinib (thyroid cancer) product — about 64% of these Medicaid prescriptions.

cabozantinib 40 MG Oral Tablet Most dispensed

2,468 Medicaid prescriptions (Q1–Q4 2025) 64% of Cabozantinib (thyroid cancer) prescriptions shown $58.3M paid by Medicaid, before rebates ≈ $23,623 per prescription, before rebates

1 of 4 listed NDCs had Medicaid claims. RxNorm 1790169

cabozantinib 20 MG Oral Tablet

883 Medicaid prescriptions (Q1–Q4 2025) 23% of Cabozantinib (thyroid cancer) prescriptions shown $24.1M paid by Medicaid, before rebates ≈ $27,293 per prescription, before rebates

1 of 4 listed NDCs had Medicaid claims. RxNorm 1790161

cabozantinib 60 MG Oral Tablet

465 Medicaid prescriptions (Q1–Q4 2025) 12% of Cabozantinib (thyroid cancer) prescriptions shown $11.2M paid by Medicaid, before rebates ≈ $24,129 per prescription, before rebates

1 of 5 listed NDCs had Medicaid claims. RxNorm 1790173

Other Cabozantinib (thyroid cancer) products: packs and listings not matched to one strength and form

37 Medicaid prescriptions (Q2–Q4 2025) <1% of Cabozantinib (thyroid cancer) prescriptions shown $179,636 paid by Medicaid, before rebates ≈ $4,855 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims.

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 4 of the 16 listed Cabozantinib (thyroid cancer) NDCs had Medicaid claims.

Cabozantinib (thyroid cancer) Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Cabozantinib recalls since July 2021.

✅No Cabozantinib recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Cabozantinib (thyroid cancer) in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
2
Strengths
5
Forms in current FDA listings
0 of 2
In current FDA listings No current FDA listing
Ingredient (IN) Cabozantinib (thyroid cancer) RxCUI 1363268
  1. Dose form (SCDF) Oral Capsule RxCUI 1363272
    No current FDA listing
    Its 2 strengths (SCD)
  2. Dose form (SCDF) Oral Tablet RxCUI 1790160
    No current FDA listing
    Its 3 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Cabozantinib (thyroid cancer) Brand Names

Cabozantinib (thyroid cancer) has 2 brand names on record: Cometriq and Cabometyx. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Cometriq the first brand, 2012 Cabometyx 2016

Sources for This Cabozantinib (thyroid cancer) Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Oct 19, 2025, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Cabozantinib (thyroid cancer).
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
1
Linked representative label ⓘ
Exelixis, Inc.
Linked label effective
Oct 19, 2025
Composite sections available
22
Linked SPL Set ID
3850cce2-6137-42e5-a792-d318c4a4b3b5
Linked SPL Document ID
e8cdcbdc-d863-4d48-af3e-a8926b9ab017
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Exelixis, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →